Search Results - "Aubele, P."

Case report: Sustained complete remission with all-oral MEPED therapy in a patient with Hodgkin's disease developing resistance to pembrolizumab by Reuthner, K, Aubele, P, Menhart, K, Rath, P, Harrer, D C, Herr, W, Hahn, J, Vogelhuber, M, Heudobler, D, Lueke, F, Reichle, A, Grube, M

“…Targeted chemotherapy and immune checkpoint inhibitors (ICPi) have expanded the spectrum of therapies for patients with relapsed/refractory (r/r) Hodgkin's…”
Get full text

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial by von Einem, J. C., Heinemann, V., von Weikersthal, L. Fischer, Vehling-Kaiser, U., Stauch, M., Hass, H. G., Decker, T., Klein, S., Held, S., Jung, A., Kirchner, T., Haas, M., Holch, J., Michl, M., Aubele, P., Boeck, S., Schulz, C., Giessen, C., Stintzing, S., Modest, D. P.

“…Purpose AIO KRK-0104 investigated first-line therapy of metastatic colorectal cancer (mCRC) with cetuximab, capecitabine and irinotecan versus cetuximab,…”
Get full text

Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status by Modest, Dominik P, Stintzing, Sebastian, Laubender, Ruediger P, Neumann, Jens, Jung, Andreas, Giessen, Clemens, Haas, Michael, Aubele, Philipp, Schulz, Christoph, Boeck, Stefan, Stemmler, Hans-Joachim, Kirchner, Thomas, Heinemann, Volker

“…This retrospective study investigated the clinical characteristics of patients with metastatic colorectal cancer (mCRC) depending on the KRAS status, thereby…”
Get full text

Case report: Sustained complete remission with all-oral MEPED therapy in a patient with Hodgkin's disease developing resistance to pembrolizumab by Reuthner, K, Aubele, P, Menhart, K, Rath, P, Harrer, D C, Herr, W, Hahn, J, Vogelhuber, M, Heudobler, D, Lueke, F, Reichle, A, Grube, M

“…Targeted chemotherapy and immune checkpoint inhibitors (ICPi) have expanded the spectrum of therapies for patients with relapsed/refractory (r/r) Hodgkin's…”
Get full text